Oruka Therapeutics Inc (ORKA) Stock Price, Quote & News

Company Profile

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. T...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 606 7910

Website: orukatx.com

Address:

855 Oak Grove Avenue, Suite 100, Menlo Park, United States

Whiskeyunderthebed May. 19 at 2:42 PM

$ORKA will add again today.

0 · Reply

Whiskeyunderthebed May. 19 at 2:13 PM

$ORKA closed positions as of this month-some big playes like Avoro and Millenninium-Point72- I suppose this has something to do with the avalanche.

0 · Reply

HLR78613 May. 19 at 1:57 PM

$ORKA another day another few dollars down.

0 · Reply

Whiskeyunderthebed May. 18 at 10:30 PM

$ORKA following the same pattern as Akero before the BO

0 · Reply

Whiskeyunderthebed May. 18 at 4:13 PM

$ORKA added here another 100 shares $59.34

0 · Reply

outlawinvestor1 May. 16 at 10:04 AM

updated paragon family of extended life biologics. https://www.paragontherapeutics.com/ $APGE $SYRE $ORKA $JBIO $CBIO

0 · Reply

Whiskeyunderthebed May. 15 at 11:13 PM

$ORKA increased position from Fairmount- plenty of other buyers all over this

0 · Reply

Whiskeyunderthebed May. 13 at 6:28 PM

$ORKA they have been playing with this thing 2 weeks now.

0 · Reply

Whiskeyunderthebed May. 12 at 1:16 PM

$ORKA BIG DOG BUY> Westfield for 313K

0 · Reply

Whiskeyunderthebed May. 12 at 12:54 PM

$ORKA time to wake up!

0 · Reply

Oruka Therapeutics reports Q1 EPS (48c), consensus (54c)

May 13, 2026, 4:03 PM EDT - 5 days ago

Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 13, 2026, 7:00 AM EDT - 6 days ago

Oruka Therapeutics Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 6 days ago

Oruka Therapeutics Earnings release: Q1 2026

2026-05-07T06:12:19.000Z - 12 days ago

Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis

HALO

May 6, 2026, 8:00 AM EDT - 13 days ago

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology

HALO

2026-04-30T10:05:54.000Z - 19 days ago

Oruka Therapeutics price target raised to $120 from $109 at Leerink

2026-04-29T10:23:22.000Z - 20 days ago

Oruka Therapeutics price target raised to $120 from $75 at H.C. Wainwright

2026-04-28T23:45:20.000Z - 20 days ago

Oruka Therapeutics $700M Secondary priced at $72.50

Apr 28, 2026, 7:42 PM EDT - 20 days ago

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

2026-04-28T12:29:34.000Z - 21 days ago

Oruka Therapeutics price target raised to $100 from $75 at UBS

2026-04-27T20:30:08.000Z - 21 days ago

Oruka Therapeutics announces $500M common stock, warrants offering

Apr 27, 2026, 4:17 PM EDT - 21 days ago

Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering

2026-04-27T20:15:11.000Z - 21 days ago

Oruka Therapeutics price target raised to $131 from $71 at Clear Street

2026-04-27T16:08:26.000Z - 21 days ago

Oruka Therapeutics rises 19.0%

2026-04-27T15:46:42.000Z - 21 days ago

Oruka Therapeutics price target raised to $160 from $78 at Barclays

2026-04-27T15:46:21.000Z - 21 days ago

Oruka Therapeutics price target raised to $165 from $85 at Wedbush

2026-04-27T15:30:18.000Z - 22 days ago

Oruka Therapeutics price target raised to $200 from $125 at Guggenheim

2026-04-27T14:34:43.000Z - 22 days ago

Oruka Therapeutics rises 23.5%

2026-04-27T14:25:09.000Z - 22 days ago

Oruka Therapeutics price target raised to $151 from $78 at BTIG

2026-04-27T13:27:36.000Z - 22 days ago

This Is Why Oruka Therapeutics Stock (ORKA) Soared Today

2026-04-27T12:23:19.000Z - 22 days ago

Oruka Therapeutics announces interim results from EVERLAST-A trial

Apr 27, 2026, 8:00 AM EDT - 22 days ago

Oruka Therapeutics Transcript: Status update

Apr 27, 2026, 8:00 AM EDT - 22 days ago

Oruka Therapeutics Press release: Status update

Apr 27, 2026, 8:00 AM EDT - 22 days ago

Oruka Therapeutics Slides: Status update

Apr 27, 2026, 7:00 AM EDT - 22 days ago

Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis

Apr 26, 2026, 12:00 PM EDT - 22 days ago

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026

Apr 17, 2026, 8:00 AM EDT - 4 weeks ago

Oruka Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 weeks ago

Oruka Therapeutics Proxy statement: Proxy filing

2026-04-15T12:01:20.000Z - 4 weeks ago

Oruka Therapeutics price target raised to $85 from $45 at Wedbush

Apr 2, 2026, 8:00 AM EDT - 6 weeks ago

Oruka Therapeutics Registration statement: Registration filing

Mar 12, 2026, 4:05 PM EDT - 2 months ago

Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 12, 2026, 7:00 AM EDT - 2 months ago

Oruka Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 2 months ago

Oruka Therapeutics Annual report: Q4 2025

Mar 11, 2026, 1:00 PM EDT - 2 months ago

Oruka Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Feb 9, 2026, 7:00 AM EST - 3 months ago

Oruka Therapeutics to Participate in Multiple Upcoming Conferences

Jan 15, 2026, 12:00 PM EST - 4 months ago

Oruka Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 4 months ago

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

Jan 12, 2026, 7:00 AM EST - 4 months ago

Oruka Therapeutics Slides: Corporate presentation

Jan 6, 2026, 7:00 AM EST - 4 months ago

Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 4:01 PM EST - 5 months ago

Oruka Therapeutics Announces New Board Member and Board Transition

Nov 12, 2025, 4:05 PM EST - 6 months ago

Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:00 PM EST - 6 months ago

Oruka Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 4:00 PM EST - 6 months ago

Oruka Therapeutics Quarterly report: Q3 2025

Nov 11, 2025, 4:40 PM EST - 6 months ago

Oruka Therapeutics Transcript: Stifel 2025 Healthcare Conference

Oct 29, 2025, 7:00 AM EDT - 7 months ago

Oruka Therapeutics to Present at Multiple November Investor Conferences

Oct 14, 2025, 8:00 AM EDT - 7 months ago

Oruka Therapeutics Registration statement: Registration Filing

Oct 14, 2025, 8:00 AM EDT - 7 months ago

Oruka Therapeutics Registration statement: Registration Filing

Oct 3, 2025, 8:00 AM EDT - 8 months ago

Oruka Therapeutics Registration statement: Registration Filing

Oct 3, 2025, 8:00 AM EDT - 8 months ago

Oruka Therapeutics Registration statement: Registration Filing

Sep 18, 2025, 7:15 AM EDT - 8 months ago

Oruka Therapeutics Slides: Study Presentation

Sep 18, 2025, 7:00 AM EDT - 8 months ago

Oruka Therapeutics Slides: Corporate Presentation

Sep 18, 2025, 7:00 AM EDT - 8 months ago

Oruka Therapeutics Slides: Study Presentation

Sep 17, 2025, 1:02 AM EDT - 8 months ago

Oruka Therapeutics Announces $180 Million Private Placement

Sep 17, 2025, 1:00 AM EDT - 8 months ago

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

Aug 11, 2025, 4:04 PM EDT - 10 months ago

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 11, 2025, 7:00 AM EDT - 10 months ago

Oruka Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 10 months ago

Oruka Therapeutics Quarterly report: Q2 2025

Jul 21, 2025, 7:00 AM EDT - 10 months ago

Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

Jul 1, 2025, 4:01 PM EDT - 11 months ago

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer

May 21, 2025, 7:00 AM EDT - 1 year ago

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 4:01 PM EDT - 1 year ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

May 14, 2025, 4:15 PM EDT - 1 year ago

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 12:00 AM EDT - 1 year ago

Oruka Therapeutics Quarterly report: Q1 2025

Apr 29, 2025, 7:00 AM EDT - 1 year ago

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Oruka Therapeutics Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Oruka Therapeutics Proxy statement: Proxy Filing

Mar 7, 2025, 8:30 AM EST - 1 year ago

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Mar 6, 2025, 4:09 PM EST - 1 year ago

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 5, 2025, 6:00 PM EST - 1 year ago

Oruka Therapeutics Earnings release: Q4 2024

Mar 5, 2025, 6:00 PM EST - 1 year ago

Oruka Therapeutics Annual report: Q4 2024

Mar 4, 2025, 10:30 AM EST - 1 year ago

Oruka Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 19, 2025, 7:00 AM EST - 1 year ago

Oruka Therapeutics to Present at Multiple March Investor Conferences

Dec 19, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

Dec 18, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

Nov 14, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics Registration statement: Registration Filing

Nov 13, 2024, 4:25 PM EST - 1 year ago

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics Earnings release: Q3 2024

Oct 18, 2024, 8:00 AM EDT - 1 year ago

Oruka Therapeutics Proxy statement: Proxy Filing

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Oruka Therapeutics Proxy statement: Proxy Filing

Sep 25, 2024, 7:08 AM EDT - 1 year ago

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

Sep 12, 2024, 7:05 AM EDT - 1 year ago

Oruka Therapeutics Announces $200 Million Private Placement

Aug 29, 2024, 4:50 PM EDT - 1 year ago

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

Aug 26, 2024, 7:30 PM EDT - 1 year ago

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

Aug 23, 2024, 4:30 PM EDT - 1 year ago

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

Aug 16, 2024, 4:15 PM EDT - 1 year ago

ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics

Aug 1, 2024, 4:15 PM EDT - 1 year ago

ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update

May 10, 2024, 6:34 PM EDT - 2 years ago

ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

Apr 25, 2024, 4:15 PM EDT - 2 years ago

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

Apr 5, 2024, 1:27 PM EDT - 2 years ago

ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

Apr 3, 2024, 11:38 AM EDT - 2 years ago

Arca Biopharma stock ($ABIO) soars on merger news

Apr 3, 2024, 7:30 AM EDT - 2 years ago

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

Feb 1, 2024, 4:35 PM EST - 2 years ago

ARCA biopharma Announces 2023 Financial Results

Dec 19, 2023, 7:00 AM EST - 2 years ago

Oruka Therapeutics Proxy statement: Proxy Filing

Dec 19, 2023, 7:00 AM EST - 2 years ago

Oruka Therapeutics Proxy statement: Proxy Filing

Oct 18, 2023, 4:25 PM EDT - 2 years ago

ARCA biopharma Announces Third Quarter 2023 Financial Results

Jul 21, 2023, 4:25 PM EDT - 3 years ago

ARCA biopharma Announces Second Quarter 2023 Financial Results

Apr 24, 2023, 4:25 PM EDT - 3 years ago

ARCA biopharma Announces First Quarter 2023 Financial Results

Feb 24, 2023, 4:20 PM EST - 3 years ago

ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update

Dec 19, 2022, 4:05 PM EST - 3 years ago

James Flynn Joins ARCA biopharma Board of Directors

Nov 3, 2022, 8:00 AM EDT - 3 years ago

Oruka Therapeutics Proxy statement: Proxy Filing

Nov 3, 2022, 8:00 AM EDT - 3 years ago

Oruka Therapeutics Proxy statement: Proxy Filing

Oct 28, 2022, 4:15 PM EDT - 3 years ago

ARCA biopharma Announces Third Quarter 2022 Financial Results

Whiskeyunderthebed May. 19 at 2:42 PM

$ORKA will add again today.

0 · Reply

Whiskeyunderthebed May. 19 at 2:13 PM

$ORKA closed positions as of this month-some big playes like Avoro and Millenninium-Point72- I suppose this has something to do with the avalanche.

0 · Reply

HLR78613 May. 19 at 1:57 PM

$ORKA another day another few dollars down.

0 · Reply

Whiskeyunderthebed May. 18 at 10:30 PM

$ORKA following the same pattern as Akero before the BO

0 · Reply

Whiskeyunderthebed May. 18 at 4:13 PM

$ORKA added here another 100 shares $59.34

0 · Reply

outlawinvestor1 May. 16 at 10:04 AM

updated paragon family of extended life biologics. https://www.paragontherapeutics.com/ $APGE $SYRE $ORKA $JBIO $CBIO

0 · Reply

Whiskeyunderthebed May. 15 at 11:13 PM

$ORKA increased position from Fairmount- plenty of other buyers all over this

0 · Reply

Whiskeyunderthebed May. 13 at 6:28 PM

$ORKA they have been playing with this thing 2 weeks now.

0 · Reply

Whiskeyunderthebed May. 12 at 1:16 PM

$ORKA BIG DOG BUY> Westfield for 313K

0 · Reply

Whiskeyunderthebed May. 12 at 12:54 PM

$ORKA time to wake up!

0 · Reply

thesheiktrader May. 11 at 12:57 PM

$ORKA this week we can see around 80 Alain

1 · Reply

Whiskeyunderthebed May. 7 at 3:37 PM

$ORKA picked up another 100 shares at $64.50

0 · Reply

Whiskeyunderthebed May. 7 at 1:11 PM

$ORKA

0 · Reply

Whiskeyunderthebed May. 7 at 12:52 PM

$ORKA big new buy from Jennison yesterday-176K

0 · Reply

AbovetheGreenLine May. 5 at 7:15 PM

Swing Trade Buy on the Close for Oruka Thera. $ORKA. https://abovethegreenline.com/wp-content/uploads/2021/01/ST-1.jpg https://zpr.io/tajDA

0 · Reply

erpy May. 5 at 7:14 PM

$ORKA Lets go baby !!! Rockets. Yahooo

0 · Reply

Whiskeyunderthebed May. 4 at 7:42 PM

$ORKA

1 · Reply

Jonita May. 4 at 7:33 PM

$ORKA in in in

0 · Reply

Whiskeyunderthebed May. 4 at 5:59 PM

$ORKA adding again at $64.50.

0 · Reply

Whiskeyunderthebed May. 4 at 1:33 PM

$ORKA Floor here-finally at $62.40

1 · Reply

cruzin May. 4 at 12:33 PM

$MLTX $ORKA Thanks for the info. Appreciate you taking the time to write it. Given this, are you still Bullish on $ORKA?

0 · Reply

Market Cap	3.74B
Revenue (ttm)	0.00
Net Income (ttm)	-105.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,906,000
Avg Vol	1,601,050
Day's Range	N/A - N/A
Shares Out	60.31M
Stochastic %K	6%
Beta	-0.20
Analysts	Strong Sell
Price Target	$141.31